Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic
Abstract
Voxvoganan is a synthetic antimicrobial peptidomimetic designed by applying the principles of natural antimicrobial peptides sharing many of the attractive properties, such as a wide antimicrobial spectrum and fast antimicrobial action. In contrast to the natural peptides that typically consist of 15-25 residues, voxvoganan contains only three amino acids, comparable to a classical small molecule drug, and can be manufactured on an industrial scale using solution phase methods. Voxvoganan has been developed both as a drug for the early treatment of respiratory viral infection and as an antimicrobial active pharmaceutical ingredient in medical devices to avoid microbial fouling, thus reducing the infection risk connected with the use of these devices. During development, voxvoganan has been through toxicology and safety studies as well as Phase 1 and 2 clinical studies. When voxvoganan hits the market as a first-in-class drug, the unique potential of antimicrobial peptides will finally reach patients.
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.